Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Ans Van Der Ploeg

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Glycogen Storage Disease Type II

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Concepts & Ideas

Age of Onset

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Van der Beek N A M E; Hagemans M L C; Reuser A J J; Hop W C J; Van der Ploeg A T; Van Doorn P A; Wokke J H J
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
van der Beek N A M E; Soliman O I I; van Capelle C I; Geleijnse M L; Vletter W B; Kroos M A; Reuser A J J; Frohn-Mulder I M E; van Doorn P A; van der Ploeg A T
Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities.
van der Ploeg Ans T; Reuser Arnold J J
Pompe's disease.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ans Van Der Ploeg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Van der Beek N A M E; Hagemans M L C; Reuser A J J; Hop W C J; Van der Ploeg A T; Van Doorn P A; Wokke J H J
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
Neuromuscular disorders : NMD 2009;19(2):113-7.
2008: van der Beek N A M E; Soliman O I I; van Capelle C I; Geleijnse M L; Vletter W B; Kroos M A; Reuser A J J; Frohn-Mulder I M E; van Doorn P A; van der Ploeg A T
Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities.
Journal of the neurological sciences 2008;275(1-2):46-50.
2008: van der Ploeg Ans T; Reuser Arnold J J
Pompe's disease.
Lancet 2008;372(9646):1342-53.
2008: Soliman O I I; van der Beek N A M E; van Doorn P A; Vletter W B; Nemes A; Van Dalen B M; ten Cate F J; van der Ploeg A T; Geleijnse M L
Cardiac involvement in adults with Pompe disease.
Journal of internal medicine 2008;264(4):333-9.
2008: Kroos Marian A; Mullaart Reinier A; Van Vliet Laura; Pomponio Robert J; Amartino Hernan; Kolodny Edwin H; Pastores Gregory M; Wevers Ron A; Van der Ploeg Ans T; Halley Dicky J J; Reuser Arnold J J
p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease?
European journal of human genetics : EJHG 2008;16(8):875-9.
2008: van Capelle C I; Winkel L P F; Hagemans M L C; Shapira S K; Arts W F M; van Doorn P A; Hop W C J; Reuser A J J; van der Ploeg A T
Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease.
Neuromuscular disorders : NMD 2008;18(6):447-52.
2008: Wraith J Edmond; Scarpa Maurizio; Beck Michael; Bodamer Olaf A; De Meirleir Linda; Guffon Nathalie; Meldgaard Lund Allan; Malm Gunilla; Van der Ploeg Ans T; Zeman Jiri
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
European journal of pediatrics 2008;167(3):267-77.
2008: Drost Maarten R; Schaart Gert; van Dijk Paul; van Capelle Carine I; van der Vusse Ger J; Delhaas Tammo; van der Ploeg Ans T; Reuser Arnold J J
Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease.
Muscle & nerve 2008;37(2):251-5.
2007: Hagemans M L C; Laforêt P; Hop W J C; Merkies I S J; Van Doorn P A; Reuser A J J; Van der Ploeg A T
Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale.
Neuromuscular disorders : NMD 2007;17(7):537-43.
2007: Hagemans Marloes L C; van Schie Sabine P M; Janssens A Cecile J W; van Doorn Pieter A; Reuser Arnold J J; van der Ploeg Ans T
Fatigue: an important feature of late-onset Pompe disease.
Journal of neurology 2007;254(7):941-5.
2007: Kroos M A; Pomponio R J; Hagemans M L; Keulemans J L M; Phipps M; DeRiso M; Palmer R E; Ausems M G E M; Van der Beek N A M E; Van Diggelen O P; Halley D J J; Van der Ploeg A T; Reuser A J J
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Neurology 2007;68(2):110-5.
2007: Okumiya Toshika; Kroos Marian A; Vliet Laura Van; Takeuchi Hiroaki; Van der Ploeg Ans T; Reuser Arnold J J
Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II.
Molecular genetics and metabolism 2007;90(1):49-57.
2006: Kroos M; Manta P; Mavridou I; Muntoni F; Halley D; Van der Helm R; Zaifeiriou D; Van der Ploeg A; Reuser A; Michelakakis H
Seven cases of Pompe disease from Greece.
Journal of inherited metabolic disease 2006;29(4):556-63.
2006: van der Beek N A M E; Hagemans M L C; van der Ploeg A T; Reuser A J J; van Doorn P A
Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
Acta neurologica Belgica 2006;106(2):82-6.
2006: Hagemans M L C; Hop W J C; Van Doorn P A; Reuser A J J; Van der Ploeg A T
Course of disability and respiratory function in untreated late-onset Pompe disease.
Neurology 2006;66(4):581-3.
2005: Winkel Léon P F; Hagemans Marloes L C; van Doorn Pieter A; Loonen M Christa B; Hop Wim J C; Reuser Arnold J J; van der Ploeg Ans T
The natural course of non-classic Pompe's disease; a review of 225 published cases.
Journal of neurology 2005;252(8):875-84.
2005: Hagemans M L C; Winkel L P F; Hop W C J; Reuser A J J; Van Doorn P A; Van der Ploeg A T
Disease severity in children and adults with Pompe disease related to age and disease duration.
Neurology 2005;64(12):2139-41.
2005: Hagemans M L C; Winkel L P F; Van Doorn P A; Hop W J C; Loonen M C B; Reuser A J J; Van der Ploeg A T
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Brain : a journal of neurology 2005;128(Pt 3):671-7.
2004: Hagemans M L C; Janssens A C J W; Winkel L P F; Sieradzan K A; Reuser A J J; Van Doorn P A; Van der Ploeg A T
Late-onset Pompe disease primarily affects quality of life in physical health domains.
Neurology 2004;63(9):1688-92.
2004: Kamphoven Joep H J; de Ruiter Martijn M; Winkel Leon P F; Van den Hout Hannerieke M P; Bijman Jan; De Zeeuw Chris I; Hoeve Hans L; Van Zanten Bert A; Van der Ploeg Ans T; Reuser Arnold J J
Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse.
Neurobiology of disease 2004;16(1):14-20.
2004: Kroos Marian A; Kirschner Janbernd; Gellerich Frank N; Hermans Monique M P; Van Der Ploeg Ans T; Reuser Arnold J J; Korinthenberg Rudolf
A case of childhood Pompe disease demonstrating phenotypic variability of p.Asp645Asn.
Neuromuscular disorders : NMD 2004;14(6):371-4.
2004: Van den Hout Johanna M P; Kamphoven Joep H J; Winkel Léon P F; Arts Willem F M; De Klerk Johannes B C; Loonen M Christa B; Vulto Arnold G; Cromme-Dijkhuis Adri; Weisglas-Kuperus Nynke; Hop Wim; Van Hirtum Hans; Van Diggelen Otto P; Boer Marijke; Kroos Marian A; Van Doorn Pieter A; Van der Voort Edwin; Sibbles Barbara; Van Corven Emiel J J M; Brakenhoff Just P J; Van Hove Johan; Smeitink Jan A M; de Jong Gerard; Reuser Arnold J J; Van der Ploeg Ans T
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Pediatrics 2004;113(5):e448-57.
2004: Kleijer W J; van Diggelen O P; Halley D J; van der Ploeg A T; Mancini G M
[From gene to disease; Krabbe disease and galactosylceramidase deficiency]
Nederlands tijdschrift voor geneeskunde 2004;148(17):826-8.
2004: Winkel Léon P F; Van den Hout Johanna M P; Kamphoven Joep H J; Disseldorp Janus A M; Remmerswaal Maaike; Arts Willem F M; Loonen M Christa B; Vulto Arnold G; Van Doorn Pieter A; De Jong Gerard; Hop Wim; Smit G Peter A; Shapira Stuart K; Boer Marijke A; van Diggelen Otto P; Reuser Arnold J J; Van der Ploeg Ans T
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Annals of neurology 2004;55(4):495-502.
2004: Hermans Monique M P; van Leenen Dik; Kroos Marian A; Beesley Clare E; Van Der Ploeg Ans T; Sakuraba Hitoshi; Wevers Ron; Kleijer Wim; Michelakakis Helen; Kirk Edwin P; Fletcher Janice; Bosshard Nils; Basel-Vanagaite Lina; Besley Guy; Reuser Arnold J J
Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.
Human mutation 2004;23(1):47-56.
2003: van den Hout Hannerieke M P; Hop Wim; van Diggelen Otto P; Smeitink Jan A M; Smit G Peter A; Poll-The Bwee-Tien T; Bakker Henk D; Loonen M Christa B; de Klerk Johannis B C; Reuser Arnold J J; van der Ploeg Ans T
The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.
Pediatrics 2003;112(2):332-40.
2003: Winkel Léon P F; Kamphoven Joep H J; van den Hout Hannerieke J M P; Severijnen Lies A; van Doorn Pieter A; Reuser Arnold J J; van der Ploeg Ans T
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Muscle & nerve 2003;27(6):743-51.
2002: Reuser Arnold J J; Van Den Hout Hannerieke; Bijvoet Agnes G A; Kroos Marian A; Verbeet Martin P; Van Der Ploeg Ans T
Enzyme therapy for Pompe disease: from science to industrial enterprise.
European journal of pediatrics 2002;161 Suppl 1():S106-11.
2001: Van den Hout J M; Reuser A J; de Klerk J B; Arts W F; Smeitink J A; Van der Ploeg A T
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
Journal of inherited metabolic disease 2001;24(2):266-74.
2001: Kamphoven J H; Stubenitsky R; Reuser A J; Van Der Ploeg A T; Verdouw P D; Duncker D J
Cardiac remodeling and contractile function in acid alpha-glucosidase knockout mice.
Physiological genomics 2001;5(4):171-9.
2000: Van den Hout H; Reuser A J; Vulto A G; Loonen M C; Cromme-Dijkhuis A; Van der Ploeg A T
Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.
Lancet 2000;356(9227):397-8.
1999: Bijvoet A G; Van Hirtum H; Vermey M; Van Leenen D; Van Der Ploeg A T; Mooi W J; Reuser A J
Pathological features of glycogen storage disease type II highlighted in the knockout mouse model.
The Journal of pathology 1999;189(3):416-24.
1999: Bijvoet A G; Van Hirtum H; Kroos M A; Van de Kamp E H; Schoneveld O; Visser P; Brakenhoff J P; Weggeman M; van Corven E J; Van der Ploeg A T; Reuser A J
Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II.
Human molecular genetics 1999;8(12):2145-53.
1999: Ausems M G; Verbiest J; Hermans M P; Kroos M A; Beemer F A; Wokke J H; Sandkuijl L A; Reuser A J; van der Ploeg A T
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.
European journal of human genetics : EJHG 1999;7(6):713-6.
1999: Ausems M G; ten Berg K; Kroos M A; van Diggelen O P; Wevers R A; Poorthuis B J; Niezen-Koning K E; van der Ploeg A T; Beemer F A; Reuser A J; Sandkuijl L A; Wokke J H
Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency.
Community genetics 1999;2(2-3):91-6.
1998: Bijvoet A G; Kroos M A; Pieper F R; Van der Vliet M; De Boer H A; Van der Ploeg A T; Verbeet M P; Reuser A J
Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice.
Human molecular genetics 1998;7(11):1815-24.
1998: Bijvoet A G; van de Kamp E H; Kroos M A; Ding J H; Yang B Z; Visser P; Bakker C E; Verbeet M P; Oostra B A; Reuser A J; van der Ploeg A T
Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease.
Human molecular genetics 1998;7(1):53-62.
1998: Hermans M M; Kroos M A; Smeitink J A; van der Ploeg A T; Kleijer W J; Reuser A J
Glycogen Storage Disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry.
Human mutation 1998;11(3):209-15.
1997: Cnossen M H; van der Est M N; Breuning M H; van Asperen C J; Breslau-Siderius E J; van der Ploeg A T; de Goede-Bolder A; van den Ouweland A M; Halley D J; Niermeijer M F
Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1?
Human mutation 1997;9(5):458-64.
1996: Bijvoet A G; Kroos M A; Pieper F R; de Boer H A; Reuser A J; van der Ploeg A T; Verbeet M P
Expression of cDNA-encoded human acid alpha-glucosidase in milk of transgenic mice.
Biochimica et biophysica acta 1996;1308(2):93-6.
1995: Fuller M; Van der Ploeg A; Reuser A J; Anson D S; Hopwood J J
Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.
European journal of biochemistry / FEBS 1995;234(3):903-9.
1995: Kleijer W J; van der Kraan M; Kroos M A; Groener J E; van Diggelen O P; Reuser A J; van der Ploeg A T
Prenatal diagnosis of glycogen storage disease type II: enzyme assay or mutation analysis?
Pediatric research 1995;38(1):103-6.
1995: Reuser A J; Kroos M A; Hermans M M; Bijvoet A G; Verbeet M P; Van Diggelen O P; Kleijer W J; Van der Ploeg A T
Glycogenosis type II (acid maltase deficiency).
Muscle & nerve 1995;3():S61-9.
1993: Willemsen R; van der Ploeg A T; Busch H F; Zondervan P E; Van Noorden C J; Reuser A J
Synthesis and in situ localization of lysosomal alpha-glucosidase in muscle of an unusual variant of glycogen storage disease type II.
Ultrastructural pathology 1993;17(5):515-27.
1991: Van der Ploeg A T; Kroos M A; Willemsen R; Brons N H; Reuser A J
Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice.
The Journal of clinical investigation 1991;87(2):513-8.
1990: Hoefsloot L H; Willemsen R; Kroos M A; Hoogeveen-Westerveld M; Hermans M M; Van der Ploeg A T; Oostra B A; Reuser A J
Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells.
The Biochemical journal 1990;272(2):485-92.
1990: van der Ploeg A T; van der Kraaij A M; Willemsen R; Kroos M A; Loonen M C; Koster J F; Reuser A J
Rat heart perfusion as model system for enzyme replacement therapy in glycogenosis type II.
Pediatric research 1990;28(4):344-7.
1990: Willemsen R; Wisselaar H A; van der Ploeg A T
Plasmalemmal vesicles are involved in transendothelial transport of albumin, lysosomal enzymes and mannose 6-phosphate receptor fragments in capillary endothelium.
European journal of cell biology 1990;51(2):235-41.
1990: Hoefsloot L H; van der Ploeg A T; Kroos M A; Hoogeveen-Westerveld M; Oostra B A; Reuser A J
Adult and infantile glycogenosis type II in one family, explained by allelic diversity.
American journal of human genetics 1990;46(1):45-52.
1989: Van der Ploeg A T; Hoefsloot L H; Hoogeveen-Westerveld M; Petersen E M; Reuser A J
Glycogenosis type II: protein and DNA analysis in five South African families from various ethnic origins.
American journal of human genetics 1989;44(6):787-93.
1989: Van der Ploeg A T; Kroos M A; Swallow D M; Reuser A J
An investigation of the possible influence of neutral alpha-glucosidases on the clinical heterogeneity of glycogenosis type II.
Annals of human genetics 1989;53(Pt 2):185-92.
1989: Swallow D M; Kroos M; Van der Ploeg A T; Griffiths B; Islam I; Marenah C B; Reuser A J
An investigation of the properties and possible clinical significance of the lysosomal alpha-glucosidase GAA*2 allele.
Annals of human genetics 1989;53(Pt 2):177-84.
1988: van der Ploeg A T; Bolhuis P A; Wolterman R A; Visser J W; Loonen M C; Busch H F; Reuser A J
Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells.
Journal of neurology 1988;235(7):392-6.
1988: Van der Ploeg A T; Loonen M C; Bolhuis P A; Busch H M; Reuser A J; Galjaard H
Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle.
Pediatric research 1988;24(1):90-4.
1987: van der Ploeg A T; Kroos M; van Dongen J M; Visser W J; Bolhuis P A; Loonen M C; Reuser A J
Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid alpha-glucosidase.
Journal of the neurological sciences 1987;79(3):327-36.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Ans Van Der Ploeg

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Ans Van Der Ploeg (preview)

All Publications